LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for APOE4 Homozygote AD

LX1001 Long-Term Follow-up Study (NCT05400330)

Overview

This Phase 1 long-term follow-up (LTFU) study is evaluating the extended safety profile of LX1001, an adeno-associated virus (AAV) serotype rh.10 gene therapy vector expressing human [APOE2](/entities/apoe2), in participants who are homozygous for the [APOE4](/genes/apoe) allele and have been diagnosed with [Alzheimer's disease](/diseases/alzheimers-disease) (AD). LX1001 was previously administered in the parent study [NCT03634007](/clinical-trials/nct03634007-lx1001-phase-1-2), and this LTFU study tracks participants for up to 260 weeks (5 years) post-administration.

LX1001 Long-Term Follow-up Study (NCT05400330)

Overview

This Phase 1 long-term follow-up (LTFU) study is evaluating the extended safety profile of LX1001, an adeno-associated virus (AAV) serotype rh.10 gene therapy vector expressing human [APOE2](/entities/apoe2), in participants who are homozygous for the [APOE4](/genes/apoe) allele and have been diagnosed with [Alzheimer's disease](/diseases/alzheimers-disease) (AD). LX1001 was previously administered in the parent study [NCT03634007](/clinical-trials/nct03634007-lx1001-phase-1-2), and this LTFU study tracks participants for up to 260 weeks (5 years) post-administration.

The therapeutic rationale is that delivering the [APOE2](/entities/apoe2) gene directly to the central nervous system via intrathecal injection converts the APOE isoform profile from APOE4 (the strongest genetic risk factor for late-onset AD) toward APOE2, which is associated with significantly reduced AD risk and neuroprotective effects.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT05400330 |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study Type | Interventional |
| Allocation | Non-randomized (single group) |
| Intervention Model | Single arm (LTFU of prior treatment) |
| Masking | None (open-label follow-up) |
| Enrollment | 10 participants |
| Sponsor | Lexeo Therapeutics |
| Collaborators | Alzheimer's Drug Discovery Foundation, Weill Cornell Medicine |
| Start Date | May 2023 (actual) |
| Primary Completion | November 2028 (estimated) |
| Locations | PPD Orlando Research Unit (Florida), Duke University (North Carolina) |

Scientific Rationale

APOE4 Homozygosity as Highest Genetic Risk

Homozygous [APOE4](/genes/apoe) carriers represent the highest-risk population for Alzheimer's disease[@sullivan2011]:

• APOE4/4 homozygotes have a 10-12× increased risk of AD compared to APOE3/3
• APOE4 homozygous prevalence: ~1-2% of the general population, but ~10-15% of all AD cases
• Earlier onset: APOE4/4 carriers develop AD symptoms approximately 5-10 years earlier than APOE3/3 carriers
• APOE4 pathophysiology: reduced amyloid clearance, increased tau pathology, impaired lipid transport, blood-brain barrier dysfunction, and heightened neuroinflammation

APOE2 Neuroprotection

The [APOE2](/entities/apoe2) isoform (encoded by the APOE ε2 allele) is associated with:

• Reduced AD risk: APOE2 carriers have ~40-50% lower risk of AD compared to APOE3/3
• Enhanced amyloid clearance: APOE2 more effectively promotes Aβ degradation and transport
• Improved synaptic integrity: Better support of dendritic spine maintenance and neuronal repair
• Anti-inflammatory properties: Reduced microglial activation and cytokine production

Gene Therapy Approach

LX1001 delivers a functional copy of the human [APOE2](/entities/apoe2) gene directly to the CNS via intrathecal AAVrh.10 administration, enabling persistent expression of APOE2 protein in the cerebrospinal fluid and brain parenchyma. This approach bypasses the blood-brain barrier delivery challenge and achieves therapeutic levels that cannot be attained with recombinant protein or small molecule approaches.

Intervention

LX1001 Gene Therapy Vector

| Parameter | Value |
|-----------|-------|
| Agent | AAVrh.10hAPOE2 (LX1001) |
| Type | Adeno-associated virus serotype rh.10 |
| Gene Delivered | Human APOE2 complementary DNA (cDNA) |
| Route of Administration | Intrathecal injection |
| Parent Study Doses | Cohort 1: 1.4×10^10 gc/mL CSF; Cohort 2: 4.4×10^10 gc/mL CSF; Cohort 3: 1.4×10^11 gc/mL CSF; Cohort 4: 1.4×10^14 gc (fixed dose) |

AAVrh.10 Serotype Rationale

The AAVrh.10 serotype was selected for its favorable CNS tropism and reduced off-target distribution[@tai2017]. Compared to AAV9 (more commonly used for CNS applications), AAVrh.10 demonstrates:

• High transduction efficiency in neurons and glia
• Lower prevalence of pre-existing neutralizing antibodies in human populations
• Efficient blood-brain barrier penetration when delivered directly to CSF

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcome Measures

Primary Endpoints

| Measure | Time Frame | Description |
|---------|------------|-------------|
| Incidence of treatment-emergent adverse events | 260 weeks | All emergent adverse events collected and categorized |
| Incidence of serious adverse events | 260 weeks | All serious adverse events documented and graded |

Secondary Endpoints

| Measure | Time Frame | Description |
|---------|------------|-------------|
| CSF APOE isoform conversion | Up to 260 weeks | Conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4 profile |
| Amyloid PET scan | Up to 260 weeks | Florbetapir PET quantification of cerebral amyloid burden |
| CSF biomarkers | Up to 260 weeks | Aβ42, Aβ42/Aβ40 ratio, total tau (T-tau), phospho-tau (P-tau) |
| Quantitative MRI | Up to 260 weeks | Volumetric MRI, white matter integrity, cortical thickness |
| Cognitive and clinical assessment | Up to 260 weeks | Standardized AD cognitive batteries (specific instruments vary) |
| Tau PET scan | Up to 260 weeks | Flortaucipir PET for tau pathology burden (LX1001-01 Cohorts 3 and 4 only) |

Parent Study: NCT03634007

The parent Phase 1/2 study established LX1001 safety and dosing. Key details:

| Field | Value |
|-------|-------|
| NCT ID | NCT03634007 |
| Status | Completed (November 2024) |
| Phase | Phase 1/Phase 2 |
| Enrollment | 15 participants |
| Doses tested | 4 ascending dose levels (1.4×10^10 to 1.4×10^14 gene copies) |
| Design | Open-label, sequential cohort, dose-escalation |

Parent Study Eligibility Highlights

• APOE4 homozygotes aged 50+
• MCI due to AD or mild-to-moderate dementia due to AD
• CSF biomarkers consistent with AD pathology
• No active anti-amyloid therapy (e.g., aducanumab, lecanemab)
• Serum neutralizing anti-AAVrh10 titer <1:100

Parent Study Locations

• K2 Medical Research (Maitland, Florida)
• PPD Orlando Research Unit (Orlando, Florida)
• Weill Cornell Medicine (New York, New York)
• Duke University (Durham, North Carolina)

Mechanism of Action

APOE2 Expression and Neuroprotection

Following intrathecal administration, LX1001 transduces cells in the central nervous system (primarily ependymal cells, meningeal cells, and possibly neurons and glia), leading to sustained APOE2 protein expression in the CSF. The therapeutic mechanism involves:

LX1001 (AAVrh.10hAPOE2) intrathecal administration
↓
Transduction of CNS cells (ependymal, meningeal, neurons, glia)
↓
Persistent APOE2 protein expression in CSF and brain parenchyma
↓
Isoform conversion: APOE4 → APOE2/APOE4 heterozygote profile in CSF
↓
Neuroprotective effects:

• Enhanced Aβ clearance and degradation
• Reduced tau phosphorylation and aggregation
• Improved synaptic function and neuronal repair
• Decreased neuroinflammation
• Preserved blood-brain barrier integrity

Key Molecular Mechanisms

APOE2 expression provides neuroprotection through multiple pathways[@kelleher2023]:

Clinical Significance

First Gene Therapy for APOE4 Homozygotes

LX1001 represents a novel therapeutic approach targeting the fundamental genetic cause of AD in the highest-risk patient population. Unlike monoclonal antibodies that target amyloid downstream, LX1001 addresses the upstream APOE4 risk by converting the isoform profile toward a protective state.

Advantages Over Antibody Approaches

• Disease-modifying: Gene therapy provides persistent (multi-year) APOE2 expression rather than periodic antibody administration
• APOE4-specific: Direct targeting of the genetic risk factor rather than general amyloid clearance
• Combinable: Could potentially be combined with anti-amyloid or anti-tau therapeutics for synergistic effects
• BBB-independent: Intrathecal delivery bypasses blood-brain barrier, achieving high CNS concentrations

Challenges and Considerations

• Invasive delivery: Requires lumbar puncture/intrathecal administration
• Long-term safety: 5-year LTFU is essential to monitor for delayed adverse events
• Population specificity: Only applicable to APOE4 homozygotes (~1-2% of population)
• Unknown efficacy: This LTFU will provide early signals of biomarker and clinical effects

Cross-References

• [APOE Gene and Alzheimer's Risk](/proteins/apoe)
• [APOE2 Neuroprotection](/entities/apoe2)
• [Gene Therapy for Alzheimer's Disease](/mechanisms/gene-therapy-alzheimers)
• [APOE4 Homozygotes](/mechanisms/apoe4-homozygosity)
• [AAV Vector Delivery to CNS](/mechanisms/aav-cns-delivery)
• [Intrathecal Drug Delivery](/mechanisms/intrathecal-delivery)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
• [Parent Trial: NCT03634007 - LX1001 Phase 1/2](/clinical-trials/nct03634007-lx1001-phase-1-2)

External Links

• [ClinicalTrials.gov - NCT05400330 (LTFU Study)](https://clinicaltrials.gov/study/NCT05400330)
• [ClinicalTrials.gov - NCT03634007 (Parent Study)](https://clinicaltrials.gov/study/NCT03634007)
• [Lexeo Therapeutics - LX1001 Pipeline](https://www.lexeotx.com/pipeline)
• [Alzheimer's Drug Discovery Foundation - Gene Therapy Program](https://www.alzdiscovery.org/)

References